Literature DB >> 16891570

Alterations in stress reactivity after long-term treatment with paroxetine in women with posttraumatic stress disorder.

Eric Vermetten1, Meena Vythilingam, Christian Schmahl, Carien DE Kloet, Steven M Southwick, Dennis S Charney, J Douglas Bremner.   

Abstract

Posttraumatic stress disorder (PTSD) is typically accompanied by both acute and chronic alterations in the stress response. These alterations have mostly been described in individuals under baseline conditions, but studies have also used a challenge model to assess the role of the hypothalamic-pituitary-adrenal (HPA) axis in the stress response. The purpose of this article was to assess the effect of long-term treatment with the selective reuptake inhibitor (SSRI), paroxetine, on stress reactivity in patients with PTSD. We assessed diurnal salivary cortisol and urinary cortisol as well as cortisol, heart rate, and behavioral responses to a standardized cognitive stress challenge, in 13 female patients with chronic PTSD before and after 12 months of paroxetine treatment. Treatment resulted in a significant decrease in PTSD symptoms. Twenty-four-hour urinary cortisol was lower compared to base line after successful treatment. Treatment resulted in a decrease of salivary cortisol levels on all time points on a diurnal curve. Despite similar stress perception, cortisol response to the cognitive stress challenge resulted in a 26.5% relative decrease in stress-induced salivary cortisol with treatment. These results suggest that successful treatment with SSRI in chronic PTSD is associated with a trend for a decrease in baseline diurnal cortisol and with reduced cortisol reactivity to stress.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891570      PMCID: PMC3230329          DOI: 10.1196/annals.1364.014

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  73 in total

1.  Platelet serotonergic markers in posttraumatic stress disorder.

Authors:  Nela Pivac; Dorotea Mück-Seler; Marina Sagud; Miro Jakovljević
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2002-10       Impact factor: 5.067

Review 2.  Basal and stress-induced differences in HPA axis, 5-HT responsiveness, and hippocampal cell proliferation in two mouse lines.

Authors:  Alexa H Veenema; Jaap M Koolhaas; E Ronald de Kloet
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

3.  Basal and dexamethasone suppressed salivary cortisol concentrations in a community sample of patients with posttraumatic stress disorder.

Authors:  Steven E Lindley; Eve B Carlson; Maryse Benoit
Journal:  Biol Psychiatry       Date:  2004-05-01       Impact factor: 13.382

4.  Habituation of cortisol responses to repeated psychosocial stress-further characterization and impact of genetic factors.

Authors:  Stefan Wüst; Ilona S Federenko; Elisabeth F C van Rossum; Jan W Koper; Dirk H Hellhammer
Journal:  Psychoneuroendocrinology       Date:  2005-02       Impact factor: 4.905

5.  The ACTH response to dexamethasone in PTSD.

Authors:  Rachel Yehuda; Julia A Golier; Sarah L Halligan; Michael Meaney; Linda M Bierer
Journal:  Am J Psychiatry       Date:  2004-08       Impact factor: 18.112

6.  Cortisol and catecholamines in posttraumatic stress disorder: an epidemiologic community study.

Authors:  Elizabeth A Young; Naomi Breslau
Journal:  Arch Gen Psychiatry       Date:  2004-04

7.  Enhanced sensitivity to glucocorticoids in peripheral mononuclear leukocytes in posttraumatic stress disorder.

Authors:  Rachel Yehuda; Julia A Golier; Ren-Kui Yang; Lisa Tischler
Journal:  Biol Psychiatry       Date:  2004-06-01       Impact factor: 13.382

8.  Urinary free-cortisol levels in posttraumatic stress disorder patients.

Authors:  J W Mason; E L Giller; T R Kosten; R B Ostroff; L Podd
Journal:  J Nerv Ment Dis       Date:  1986-03       Impact factor: 2.254

9.  Hypocortisolism and increased glucocorticoid sensitivity of pro-Inflammatory cytokine production in Bosnian war refugees with posttraumatic stress disorder.

Authors:  Nicolas Rohleder; Ljiljana Joksimovic; Jutta M Wolf; Clemens Kirschbaum
Journal:  Biol Psychiatry       Date:  2004-04-01       Impact factor: 13.382

10.  Overnight metyrapone and combined dexamethasone/metyrapone tests in post-traumatic stress disorder: preliminary findings.

Authors:  Michael Kellner; Christian Otte; Alexander Yassouridis; Mildred Schick; Holger Jahn; Klaus Wiedemann
Journal:  Eur Neuropsychopharmacol       Date:  2004-08       Impact factor: 4.600

View more
  15 in total

Review 1.  How the cerebral serotonin homeostasis predicts environmental changes: a model to explain seasonal changes of brain 5-HTT as intermediate phenotype of the 5-HTTLPR.

Authors:  Jan Kalbitzer; Urs Kalbitzer; Gitte Moos Knudsen; Paul Cumming; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2013-10-23       Impact factor: 4.530

Review 2.  Pharmacological treatment of PTSD - established and new approaches.

Authors:  Thomas Steckler; Victoria Risbrough
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

3.  Combined Pharmacotherapy and Cognitive-Behavioral Therapy for Anxiety Disorders: Medication Effects, Glucocorticoids, and Attenuated Treatment Outcomes.

Authors:  Michael W Otto; R Kathryn McHugh; Kathleen M Kantak
Journal:  Clin Psychol (New York)       Date:  2010-06-08

4.  An investigation of outcome expectancies as a predictor of treatment response for combat veterans with PTSD: comparison of clinician, self-report, and biological measures.

Authors:  Matthew Price; Jessica L Maples; Tanja Jovanovic; Seth D Norrholm; Mary Heekin; Barbara O Rothbaum
Journal:  Depress Anxiety       Date:  2015-02-19       Impact factor: 6.505

Review 5.  Neuroimaging in posttraumatic stress disorder and other stress-related disorders.

Authors:  J Douglas Bremner
Journal:  Neuroimaging Clin N Am       Date:  2007-11       Impact factor: 2.264

6.  A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans.

Authors:  Barbara Olasov Rothbaum; Matthew Price; Tanja Jovanovic; Seth D Norrholm; Maryrose Gerardi; Boadie Dunlop; Michael Davis; Bekh Bradley; Erica J Duncan; Albert Rizzo; Kerry J Ressler
Journal:  Am J Psychiatry       Date:  2014-06       Impact factor: 18.112

7.  Baseline psychophysiological and cortisol reactivity as a predictor of PTSD treatment outcome in virtual reality exposure therapy.

Authors:  Seth Davin Norrholm; Tanja Jovanovic; Maryrose Gerardi; Kathryn G Breazeale; Matthew Price; Michael Davis; Erica Duncan; Kerry J Ressler; Bekh Bradley; Albert Rizzo; Peter W Tuerk; Barbara O Rothbaum
Journal:  Behav Res Ther       Date:  2016-05-07

Review 8.  Structural and functional plasticity of the human brain in posttraumatic stress disorder.

Authors:  J Douglas Bremner; Bernet Elzinga; Christian Schmahl; Eric Vermetten
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

9.  Effect of paroxetine on physiological response to stress and smoking.

Authors:  Michael Kotlyar; Mustafa al'Absi; Paul Thuras; John P Vuchetich; David E Adson; April L Nowack; Dorothy K Hatsukami
Journal:  Psychosom Med       Date:  2013-03-15       Impact factor: 4.312

Review 10.  Functional neuroimaging in post-traumatic stress disorder.

Authors:  J Douglas Bremner
Journal:  Expert Rev Neurother       Date:  2007-04       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.